Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68869 | 0.89 | MAPK1 (0.63) | MAPK1LCKKDM4EL3MBTL1GABRP | |
| SCHEMBL5700876 | 0.81 | KDM4E (0.61) | MAPK1LCKKDM4EL3MBTL1GABRP | |
| SCHEMBL990711 | 0.81 | MAPK1 (0.55) | MAPK1LCKKDM4EL3MBTL1GABRP | |
| SCHEMBL1858691 | 0.79 | POLB (0.59) | MAPK1L3MBTL1ALDH1A1LMNACYP1A2 | |
| SCHEMBL29700722 | 0.79 | GABRG2 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL197360 | 0.79 | CYP1A2 (0.50) | KDM4EL3MBTL1GABRPGABRDGABRA1 | |
| SCHEMBL29208228 | 0.79 | GABRG2 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL544241 | 0.78 | MAPK1 (0.52) | MAPK1LCKKDM4EL3MBTL1GABRP | |
| SCHEMBL13524601 | 0.78 | SIRT6 (0.67) | MAPK1LCKKDM4EL3MBTL1GABRP | |
| SCHEMBL22119742 | 0.78 | MAPK1 (0.52) | MAPK1LCKKDM4EL3MBTL1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108083599-A | For the foam Ti-base catalyst of sludge hot hydrolysis process system | 北京达源环保科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-108059205-A | For the up-flow adsorptive reactor of orthophosphates in Adsorption waste water | 北京益清源环保科技有限公司 | 2018-05-22 | — | — | CN | claimed |
| CN-107879583-A | Sludge pyrohydrolysis and anaerobic digestion integrated treatment process system | 北京达源环保科技有限公司 | 2018-04-06 | — | — | CN | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-115485273-B | N- (heterocyclyl and heterocyclylalkyl) -3-benzyl pyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2076499-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008040649-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452525-A1 | AMIDE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | MAPK1 4224/4885LCK 2470/4885KDM4E 2459/4885 |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | MAPK1 2159/4885LCK 1892/4885KDM4E 3131/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | MAPK1 3409/4885LCK 4319/4885KDM4E 4515/4885 |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | CNR2, CNR1, P2RY2 | MAPK1 1789/4885LCK 1021/4885KDM4E 2121/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | MAPK1 3645/4885LCK 4514/4885KDM4E 4522/4885 |
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | TGFBR1, TGFBR2, TGFB1 | MAPK1 443/4885LCK 834/4885KDM4E 756/4885 |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR1 | MAPK1 2159/4885LCK 1892/4885KDM4E 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.